All In Biotech

Drug Trial Radar · NCT03245229

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Aug 10, 2017

Primary completion

Sep 18, 2017

Study completion Sep 18, 2017

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Aug 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to investigate the effect of Aprocitentan (ACT-132577) at steady state on the pharmacokinetics of single-dose rosuvastatin in healthy male subjects

Conditions

  • Healthy Subjects

Interventions

  • AprocitentanDrug

    Capsule for oral administration

  • RosuvastatinDrug

    Tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax) of rosuvastatinTime frame: Up to Day 29
  2. Time to reach Cmax (tmax) of rosuvastatinTime frame: Up to Day 29
  3. Terminal half-life (t1/2) of rosuvastatinTime frame: Up to Day 29
  4. Area under the plasma concentration-time curves during a dosing interval [AUC(0-t)] of rosuvastatinTime frame: Up to Day 29
  5. Area under the plasma concentration-time curves from time 0 to inf [AUC(0-inf)] of rosuvastatinTime frame: Up to Day 29
  6. Trough (pre-dose) plasma concentrations (Ctrough) of ACT-132577Time frame: Up to Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cepha s.r.o

    Pilsen, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.